Physician profile
Monica Rebekah Davis
NPI 1376272856
$16,889.90
in general payments reported to CMS, 2019-2025
16 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $134 · 2024: $1,630 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Travel and Lodging: $4,551 · Food and Beverage: $1,689 · Consulting Fee: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,200.00 |
| Travel and Lodging | $4,551.29 |
| Food and Beverage | $1,688.61 |
| Consulting Fee | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $16,019.32 | 2023-2025 | Daybue |
| Alexion Pharmaceuticals, INC. | $146.55 | 2023-2024 | Strensiq |
| Gilead Sciences, INC. | $124.99 | 2024 | |
| Viiv Healthcare Company | $104.34 | 2024 | Dovato |
| Phathom Pharmaceuticals, INC. | $102.00 | 2024 | Voquezna |
| Eisai INC. | $101.35 | 2024 | |
| Genzyme Corporation | $77.14 | 2023-2025 | |
| Biomarin Pharmaceutical INC. | $57.18 | 2025 | Voxzogo 1.2mg, Palynziq |
| Cycle Pharmaceuticals INC | $26.06 | 2024 | Javygtor |
| Novartis Pharmaceuticals Corporation | $24.94 | 2023 | |
| Sarepta Therapeutics, INC. | $21.95 | 2025 | Elevidys |
| Medunik USA INC. | $21.77 | 2025 | Pheburane |
| Immedica Pharma US, INC. | $18.28 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $15.91 | 2024 | Airsupra |
| Ardelyx, INC. | $14.84 | 2024 | Ibsrela |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $13.28 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.